M. Giles

发表

Growth factor signalling and resistance to selective oestrogen receptor modulators and pure anti-oestrogens: the use of anti-growth factor therapies to treat or delay endocrine resistance in breast cancer.

R. Nicholson, J. Gee, I. Hutcheson, 2005, Endocrine-related cancer.

Responses to androgens of rat ventral prostate nuclear androgen‐binding sites sensitive and resistant to micrococcal nuclease

M. Giles, P. Davies, P. Thomas, 1982, The Prostate.

Bidirectional cross talk between ERα and EGFR signalling pathways regulates tamoxifen-resistant growth

R. Nicholson, J. Gee, I. Hutcheson, 2006, Breast Cancer Research and Treatment.

Impact of altered growth factor signalling on endocrine response in breast cancer and the transition from ER+ to ER− disease

R. Nicholson, I. Hutcheson, M. Giles, 2004 .

Changes in endonuclease activity during growth and regression of the Shionogi mammary carcinoma

N. Bruchovsky, P. Rennie, M. Giles, 1986, Molecular and Cellular Endocrinology.

Variability of androgen-related phenotypes in the Shionogi mammary carcinoma during growth, involution, recurrence, and progression to hormonal independence.

N. Bruchovsky, P. Rennie, M. Giles, 1985, Cancer research.

Distribution of acceptor sites for androgen-receptor complexes between transcriptionally active and inactive fractions of rat ventral prostate chromatin.

M. Giles, N. Borthwick, P. Davies, 1980, The Journal of endocrinology.

ICI 174864: A highly selective antagonist for the opioid Δ-receptor

M. Giles, D. Timms, J. Shaw, 1984 .

Growth factor signalling in endocrine and anti-growth factor resistant breast cancer

R. Nicholson, J. Gee, K. Taylor, 2007, Reviews in Endocrine and Metabolic Disorders.

ICI 174864: a highly selective antagonist for the opioid delta-receptor.

M. Giles, D. Timms, J. Shaw, 1984, European journal of pharmacology.

Regulation of transcription of the prostate genome by androgens.

K. Griffiths, M. Giles, J. Boonjawat, 1979, Journal of steroid biochemistry.

Extreme growth factor signalling can promote oestrogen receptor-α loss: therapeutic implications in breast cancer

R. Nicholson, J. Gee, M. Giles, 2004, Breast Cancer Research.

Anti-oestrogen therapy switches off tumour suppressors and proapoptotic genes in breast cancer and reveals a new therapeutic opportunity

R. Nicholson, M. Giles, J. Gee, 2008, Breast Cancer Research.